HUP0002062A2 - Eljárás metabolikus csontbetegségek diagnózisára - Google Patents

Eljárás metabolikus csontbetegségek diagnózisára

Info

Publication number
HUP0002062A2
HUP0002062A2 HU0002062A HUP0002062A HUP0002062A2 HU P0002062 A2 HUP0002062 A2 HU P0002062A2 HU 0002062 A HU0002062 A HU 0002062A HU P0002062 A HUP0002062 A HU P0002062A HU P0002062 A2 HUP0002062 A2 HU P0002062A2
Authority
HU
Hungary
Prior art keywords
binding
syndrome
production
agent
individual
Prior art date
Application number
HU0002062A
Other languages
English (en)
Inventor
Masaaki Goto
Kanji Higashio
Fumie Kobayashi
Eisuke Tsuda
Naohiro Washida
Yoshiji Yamada
Kazuki Yano
Original Assignee
Snow Brand Milk Products Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Snow Brand Milk Products Co., Ltd. filed Critical Snow Brand Milk Products Co., Ltd.
Publication of HUP0002062A2 publication Critical patent/HUP0002062A2/hu
Publication of HUP0002062A3 publication Critical patent/HUP0002062A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/108—Osteoporosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Apparatus For Radiation Diagnosis (AREA)

Abstract

A találmány tárgya immunglobulin-termelést előidéző kostimulálószignál aktivált T-sejtekre történő továbbvitelét, közelebbről CD40 :CD154-kötődést akadályozó ágens, igen előnyösen az 5c8 elnevezésű,ATCC HB 10916 nyilvántartási számú ellenanyag antigénspecifikuskötődési sajátságaival rendelkező monoklonális ellenanyag alkalmazásaCD154-blokádterápiára alkalmas gyógyszer előállítása, közelebbről aCD40 : CD154-kötődést akadályozó ágens alkalmazása proteinnel szembeniinhibitor-tünetegyüttesben szenvedő egyedben vagy ilyen tünetegyütteskialakulása kockázatának kitett egyedben a tünetegyütteskialakulásának megelőzésére, késleltetésére, káros hatásainakszuppresszálására, súlyosságának enyhítésére, alkalmas gyógyszerelőállítására. A találmány tárgya továbbá CD40 : CD154-kötődéstakadályozó ágens alkalmazása exogén proteinnel kezelt egyedben azexogén protein terápiás aktivitásának megőrzésére vagyvisszaállítására alkalmas gyógyszer előállítására. Ó
HU0002062A 1997-09-24 1998-07-31 Method for diagnosing bone dysbolism HUP0002062A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP27647597 1997-09-24
PCT/JP1998/003421 WO1999015691A1 (fr) 1997-09-24 1998-07-31 Procede permettant de diagnostiquer un dysfonctionnement du metabolisme osseux

Publications (2)

Publication Number Publication Date
HUP0002062A2 true HUP0002062A2 (hu) 2000-10-28
HUP0002062A3 HUP0002062A3 (en) 2002-09-30

Family

ID=17569976

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0002062A HUP0002062A3 (en) 1997-09-24 1998-07-31 Method for diagnosing bone dysbolism

Country Status (16)

Country Link
US (2) US6693175B2 (hu)
EP (1) EP0974671B1 (hu)
JP (1) JP4268684B2 (hu)
KR (1) KR100547395B1 (hu)
CN (1) CN1183159C (hu)
AT (1) ATE328281T1 (hu)
AU (1) AU739304B2 (hu)
CA (1) CA2269114A1 (hu)
DE (1) DE69834719D1 (hu)
HU (1) HUP0002062A3 (hu)
IL (1) IL129535A (hu)
NO (1) NO992472D0 (hu)
NZ (1) NZ335759A (hu)
RU (1) RU2203497C2 (hu)
WO (1) WO1999015691A1 (hu)
ZA (1) ZA986974B (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
TR200101146T2 (tr) 1998-10-28 2001-09-21 Sankyo Co., Ltd. Kemik-patobolizmasını tedavi edici madde.
JP3709332B2 (ja) * 2000-09-14 2005-10-26 株式会社エーシーバイオテクノロジーズ 骨粗鬆症の診断および／または骨粗鬆症骨折リスクの予測の方法
WO2002062990A1 (fr) * 2001-02-07 2002-08-15 Sankyo Company, Limited Anticorps et utilisation de cet anticorps
WO2002079256A1 (fr) * 2001-03-26 2002-10-10 Sankyo Company, Limited Anticorps et son utilisation
IL158152A0 (en) * 2001-04-03 2004-03-28 Nestle Sa Osteoprotegerin in milk
CZ20022231A3 (cs) * 2001-06-29 2003-02-12 Sankyo Company Limited Komplex skládající se z osteoklastogenezi inhibujícího faktoru a polysacharidu
EP1482978A1 (en) * 2002-03-01 2004-12-08 Sankyo Company, Limited Pharmaceutical composition comprising osteoclastogenesis inhibitory factor
US7279451B2 (en) 2002-10-25 2007-10-09 Honeywell International Inc. Compositions containing fluorine substituted olefins
AU2002343870A1 (en) * 2002-11-07 2004-06-07 Kumamoto Technology And Industry Foundation Transgenic mammal carrying ganp and utilization thereof
KR100545064B1 (ko) * 2003-05-26 2006-01-24 김현기 인간 원암단백질에 특이적인 항체를 포함하는 간경변증진단 키트
EP2024005A4 (en) * 2006-05-17 2013-01-30 Univ New York State Res Found BIOMECHANICAL METHOD FOR THE TREATMENT OF FATIBILITY AND DIABETES
WO2012051495A2 (en) 2010-10-15 2012-04-19 The Research Foundation Of State University Of New York Compositions and methods for enhancing the biological response to chemical agents and physical stimuli
RU2524616C1 (ru) * 2013-01-21 2014-07-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Владивостокский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГОУ ВПО ВГМУ Минздрава России) Способ диагностики ранней стадии ревматоидного артрита
GB201302257D0 (en) 2013-02-08 2013-03-27 Nobel Biocare Services Ag Method for measuring bone loss rate
CN106405064B (zh) * 2016-08-30 2018-10-26 嘉兴行健生物科技有限公司 一种40岁以上女性骨转换率的评估方法
CN109540818A (zh) * 2018-12-21 2019-03-29 云南农业大学 一种基于钙、磷血液生化标记选育武定鸡的方法
CN113621060B (zh) * 2020-05-07 2023-07-04 浙江瑞硕生物技术有限公司 一种opg抗体对及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
JPH04502854A (ja) * 1988-10-24 1992-05-28 カターソン，ブルース 変形性関節症の初期段階の診断、モニタリングならびに治療の方法および組成物
WO1992009697A1 (en) 1990-11-30 1992-06-11 Celtrix Laboratories, Inc. USE OF A BONE MORPHOGENETIC PROTEIN IN SYNERGISTIC COMBINATION WITH TGF-β FOR BONE REPAIR
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
CA2068389A1 (en) 1991-05-13 1992-11-14 Masahiko Sato Method for inhibiting bone resorption
MX9204303A (es) 1991-07-23 1993-11-01 Rhone Poulenc Rorer Int Factor regulador del crecimiento de osteoclasto.
US5366859A (en) * 1991-10-31 1994-11-22 Mitsubishi Petrochemical Co., Ltd. Radioimmunoassay method
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US5427954A (en) * 1992-04-29 1995-06-27 Shriner's Hospitals For Crippled Children Compositions and methods for detection and treatment of human osteoarthritis
US5578569A (en) 1993-03-12 1996-11-26 Tam; Cherk S. Method of increasing bone growth
ATE202571T1 (de) 1993-09-14 2001-07-15 Merck & Co Inc Humane protein-tyrosinphosphatase decodierende cdna
US6046033A (en) * 1994-06-27 2000-04-04 Snow Brand Milk Products Co., Ltd. Basic osteoblast growth factor II (bOGF-II)
AU4440496A (en) 1995-02-10 1996-08-22 Smithkline Beecham Corporation Use of src SH2 specific compounds to treat a bone resorption disease
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
WO1996028546A1 (en) 1995-03-15 1996-09-19 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
WO1997000317A1 (en) 1995-06-07 1997-01-03 Osteosa Inc. Osteoclast growth regulatory factor
WO1997000318A1 (en) * 1995-06-07 1997-01-03 Osteosa Inc. Osteoclast growth regulatory factor
US6613544B1 (en) * 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
JPH1057071A (ja) 1996-08-19 1998-03-03 Snow Brand Milk Prod Co Ltd 新規ｄｎａ及びそれを用いた蛋白質の製造方法
US5830850A (en) * 1996-08-28 1998-11-03 Mount Sinai School Of Medicine Of The City Of New York Methods for the treatment of bone resorption disorders, including osteoporosis
AU5901598A (en) 1996-12-20 1998-07-17 Board Of Regents, The University Of Texas System Compositions and methods of use for osteoclast inhibitory factors
EP2371962A3 (en) 1996-12-23 2011-12-21 Immunex Corporation Receptor activator of NF-KAPPA B, receptor is member of TNF receptor superfamily
US5843678A (en) 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins

Also Published As

Publication number Publication date
NZ335759A (en) 2002-02-01
US20020004207A1 (en) 2002-01-10
HUP0002062A3 (en) 2002-09-30
IL129535A (en) 2003-07-06
WO1999015691A1 (fr) 1999-04-01
RU2203497C2 (ru) 2003-04-27
US6693175B2 (en) 2004-02-17
EP0974671A8 (en) 2002-07-03
US20040033533A1 (en) 2004-02-19
NO992472L (no) 1999-05-21
ZA986974B (en) 1999-02-04
NO992472D0 (no) 1999-05-21
KR20000068916A (ko) 2000-11-25
DE69834719D1 (de) 2006-07-06
AU739304B2 (en) 2001-10-11
EP0974671B1 (en) 2006-05-31
ATE328281T1 (de) 2006-06-15
EP0974671A1 (en) 2000-01-26
US6998242B2 (en) 2006-02-14
JP4268684B2 (ja) 2009-05-27
AU8461798A (en) 1999-04-12
KR100547395B1 (ko) 2006-02-01
CN1183159C (zh) 2005-01-05
EP0974671A4 (en) 2004-10-22
CN1239515A (zh) 1999-12-22
CA2269114A1 (en) 1999-03-24
IL129535A0 (en) 2000-02-29

Similar Documents

Publication Publication Date Title
HUP0002062A2 (hu) Eljárás metabolikus csontbetegségek diagnózisára
HUP0002048A2 (hu) CD40:CD154-kötődést akadályozó ágens alkalmazása terápiás proteinnel szembeni inhibitor-tünetegyüttes kezelésére alkalmas gyógyszer előállítására
Arredouani et al. Haptoglobin directly affects T cells and suppresses T helper cell type 2 cytokine release
Markvardsen et al. Subcutaneous immunoglobulin as first‐line therapy in treatment‐naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study
Patel et al. Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis
Pichler Adverse side‐effects to biological agents
Nishimoto et al. Treatment of rheumatoid arthritis with humanized anti–interleukin‐6 receptor antibody: a multicenter, double‐blind, placebo‐controlled trial
Kocatürk et al. Looking forward to new targeted treatments for chronic spontaneous urticaria
Genovese et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two‐year radiographic and clinical outcomes
Hahn et al. Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus
Kavanaugh et al. Repeat treatment of rheumatoid arthritis patients with a murine anti‐intercellular adhesion molecule 1 monoclonal antibody
DK0942740T3 (da) Kombinationsterapi under anvendelse af et TFN-bindende protein til behandling af TFN-medierede sygdomme
NO331072B1 (no) Sammensetning som omfatter et angiogenese inhiberende middel og et anti tumor-immunoterapeutisk middel samt anvendelser av det samme.
Al Ghazal et al. Therapy of pyoderma gangrenosum in Germany: results of a survey among wound experts
MD1367C2 (ro) Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
EP1684805B8 (en) Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
Marker et al. Successful immunoapheresis of bullous autoimmune diseases: pemphigus vulgaris and pemphigoid gestationis
Brackmann et al. German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies
Fox et al. Rituximab for adolescents with haemophilia and high titre inhibitors
Pakala et al. Prevention of diabetes in NOD mice at a late stage by targeting OX40/OX40 ligand interactions
Luross et al. Escherichia coli heat‐labile enterotoxin B subunit prevents autoimmune arthritis through induction of regulatory CD4+ T cells
Mauri et al. Down‐regulation of Th1‐mediated pathology in experimental arthritis by stimulation of the Th2 arm of the immune response
Uzonna et al. Anti‐IL‐4 antibody therapy causes regression of chronic lesions caused by medium‐dose Leishmania major infection in BALB/c mice
JPH09510952A (ja) 自己免疫疾患および炎症性疾患の治療
Dunkley et al. Rituximab treatment of mild haemophilia A with inhibitors: a proposed treatment protocol

Legal Events

Date Code Title Description
FC4A Lapse of provisional application due to refusal